Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis
A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is the first-line treatment for Class III, IV, and V lupus nephritis. Among the 139 single nucleotide polymorphisms (SNPs) associated with cyclophosphamide, four SNPs, namely rs4244285, rs4802101, rs72545...
Saved in:
Main Authors: | Yen Yen Ari Indrawijaya, Laniyati Hamijoyo, Aluicia Anita Artarini, Maria Immaculata Iwo |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2023-11-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2432 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mycophenolate mofetil versus cyclophosphamide, in combination with prednisolone for lupus nephritis induction treatment: Findings from a prospective observational study
by: Rakhesh LR, et al.
Published: (2025-07-01) -
Experimental Study on Cytoflavin Pharmacological Correction of Cyclophosphamide-Induced Toxic Affections of the Liver and Kidneys
by: V. A. Kashuro, et al.
Published: (2020-05-01) -
CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study
by: Heba M. Elmaraghy, et al.
Published: (2025-06-01) -
Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center
by: Han Y, et al.
Published: (2025-07-01) -
Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01)